Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated News
Vertex Pharmaceuticals Incorporated Quantitative Score
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Vertex Pharmaceuticals Incorporated Earnings & Revenue
Vertex Pharmaceuticals Incorporated Financials
Table Compare
Compare VRTX metrics with: | |||
|---|---|---|---|
Earnings & Growth | VRTX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | VRTX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | VRTX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | VRTX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Vertex Pharmaceuticals Incorporated Income
Vertex Pharmaceuticals Incorporated Balance Sheet
Vertex Pharmaceuticals Incorporated Cash Flow
Vertex Pharmaceuticals Incorporated Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Vertex Pharmaceuticals Incorporated Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Vertex Pharmaceuticals Incorporated Executives
| Name | Role |
|---|---|
| Dr. Reshma Kewalramani FASN, M.D. | Chief Executive Officer, President & Director |
| Mr. Stuart A. Arbuckle B.Sc. | Executive Vice President & Chief Operating Officer |
| Mr. Charles F. Wagner Jr. | Executive Vice President & Chief Financial Officer |
| Dr. David M. Altshuler M.D., Ph.D. | Executive Vice President & Chief Scientific Officer |
| Dr. Ourania Tatsis Ph.D. | Executive Vice President and Chief Regulatory & Quality Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Reshma Kewalramani FASN, M.D. | Chief Executive Officer, President & Director | 1973 | 6.54M | |
| Mr. Stuart A. Arbuckle B.Sc. | Executive Vice President & Chief Operating Officer | Male | 1966 | 3.15M |
| Mr. Charles F. Wagner Jr. | Executive Vice President & Chief Financial Officer | Male | 1968 | 2.75M |
| Dr. David M. Altshuler M.D., Ph.D. | Executive Vice President & Chief Scientific Officer | 1965 | 2.39M | |
| Dr. Ourania Tatsis Ph.D. | Executive Vice President and Chief Regulatory & Quality Officer | 1970 | 2.08M |
Vertex Pharmaceuticals Incorporated Insider Trades
| Date | 13 May |
| Name | Arbuckle Stuart A |
| Role | EVP, COO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 37622 |
| Date | 1 May |
| Name | Upadhyay Suketu |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 796 |
| Date | 1 May |
| Name | Upadhyay Suketu |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 1001 |
| Date | 1 May |
| Name | Upadhyay Suketu |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 1001 |
| Date | 1 May |
| Name | Thornberry Nancy |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 398 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 13 May | Arbuckle Stuart A | EVP, COO | Acquired | A-Award | 37622 |
| 1 May | Upadhyay Suketu | Director | Acquired | A-Award | 796 |
| 1 May | Upadhyay Suketu | Director | Disposed | D-Return | 1001 |
| 1 May | Upadhyay Suketu | Director | Acquired | A-Award | 1001 |
| 1 May | Thornberry Nancy | Director | Acquired | A-Award | 398 |